Any current/future capex/capital investment/strategic investment?

Current CAPEX is ongoing, primarily focused on two projects similar to previous year's investments. Newly completed warehouse as part of infrastructure development. Rs. 181 million added to gross block in Q1, mainly for the new warehouse construction. No mention of major new CAPEX lined up distinctly for FY24 or FY25 beyond ongoing projects. Strategic investments include expanding presence in regulated markets like Europe, Australia, and New Zealand through subsidiaries and marketing partners. Investment in R&D continues strong, with Rs. 53 million spent in Q1 FY24 (~8% of operating income) to

Future growth expectations in sales/revenue/volumes?

The company expects a mid-teen growth rate in its base business, though a detailed revised guidance will be clearer after Q2 (Page 7). Growth from Novel In-house Products (NIP) is anticipated to increase significantly in coming quarters, driven by expanding sales in Rest of World (RoW), emerging, and domestic markets (Page 13-14). Revenues from Europe will start generating by end of next year once EU registrations are completed, bringing higher margins and better ROI (Page 14). Despite recent setbacks due to currency/dollar shortages and delayed shipments, the company plans to recoup lost sale

Future growth expectations in earnings/operating earnings/profits/EPS?

Management anticipates mid-teen revenue growth, with detailed revised guidance expected by end of Q2 FY24. (Page 6) Earnings before interest, taxes, depreciation, and amortization (EBITDA) for Q1 FY24 was Rs. 59 million with EBITDA margin at 8.8%, and Profit After Tax (PAT) at Rs. 2 million (0.3% margin), reflecting temporary challenges. (Page 4) Return on investment in New Innovative Products (NIPs) has begun, with Rs. 47 million revenue in Q1 FY24 from NIPs, expected to grow significantly in upcoming quarters. (Page 13, Page 4) Oral Thin Film (OTF) products recently entered European markets;

Current/ Expected Orderbook/ Pending Orders?

There were delayed orders in Q1 FY24 due to US dollar shortage in certain RoW markets, especially impacting nutraceutical sales. The postponed orders mainly arose from currency shortages; the contracts remain active. A significant portion of these deferred orders has already been received in Q2 FY24. The company anticipates the dollar shortage issue to stabilize and normalize going forward. PFI (Pharmaceutical Formulation Ingredients) business orders that were shifted from Q1 to Q2 are expected to compensate part of the lost sales. No specific quantitative figures were disclosed for the curren

Zim LaboratoriesQ1 FY24

Zim Laboratories Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138.17P/E: 200.4Market Cap: ₹741 Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects a mid-teen growth rate in its base business, though a detailed revised guidance will be clearer after Q2 (Page 7).
Growth from Novel In-house Products (NIP) is anticipated to increase significantly in coming quarters, driven by expanding sales in Rest of World (RoW), emerging, and domestic markets (Page 13-14).
Revenues from Europe will start generating by end of next year once EU registrations are completed, bringing higher margins and better ROI (Page 14).
Despite recent setbacks due to currency/dollar shortages and delayed shipments, the company plans to recoup lost sales in Pharma and market NIP products aggressively (Page 15-16).
The Oral Thin Film (OTF) segment is at an early stage but holds long-term potential as acceptance grows globally (Page 11-12).
Expansion into new markets like LATAM, Australia, and New Zealand is underway to diversify revenue sources (Page 8, 16).
R&D investment continues to support sustainable innovation aimed at long-term growth (Page 13).

Margin guidance

Category 3

Management anticipates mid-teen revenue growth, with detailed revised guidance expected by end of Q2 FY24. (Page 6)
Earnings before interest, taxes, depreciation, and amortization (EBITDA) for Q1 FY24 was Rs. 59 million with EBITDA margin at 8.8%, and Profit After Tax (PAT) at Rs. 2 million (0.3% margin), reflecting temporary challenges. (Page 4)
Return on investment in New Innovative Products (NIPs) has begun, with Rs. 47 million revenue in Q1 FY24 from NIPs, expected to grow significantly in upcoming quarters. (Page 13, Page 4)
Oral Thin Film (OTF) products recently entered European markets; revenue from these is expected to increase as marketing authorizations and filings progress. (Page 14, Page 4)
Despite near-term currency and export headwinds, management remains confident in overcoming challenges and achieving sustainable growth and profitability. (Page 4)
Margin improvement anticipated as company enters regulated markets with higher margin products. (Page 5)
Investment in R&D (~8% of operating income) supports future growth; payback improving as NIP revenue rises. (Page 4, Page 13)

See what Zim Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

- No specific mention of new fundraising through debt or equity in the provided transcript. - Utilization of consideration received on escrow shares was primarily for reducing cash credit and working capital loans, which helps lower borrowing costs going forward (Page 6). - Current CAPEX projects are ongoing but similar in scale to previous years; no indication of new debt/equity raising tied to CAPEX (Page 6). - No explicit plans or commentary related to fresh fundraising activities were discussed during the Q&A or management commentary sections. - The company is focusing on improving operational efficiency, reducing borrowing costs, and utilizing internal resources for ongoing projects. In summary, based on the available information, ZIM Laboratories has not indicated any current or imminent plans for fresh fundraising via debt or equity.

Order book

There were delayed orders in Q1 FY24 due to US dollar shortage in certain RoW markets, especially impacting nutraceutical sales.
The postponed orders mainly arose from currency shortages; the contracts remain active.
A significant portion of these deferred orders has already been received in Q2 FY24.
The company anticipates the dollar shortage issue to stabilize and normalize going forward.
PFI (Pharmaceutical Formulation Ingredients) business orders that were shifted from Q1 to Q2 are expected to compensate part of the lost sales.
No specific quantitative figures were disclosed for the current pending orderbook or overall expected order backlog.
Management indicated that more clarity on orderbook and revenue guidance will be available after Q2 FY24, as the situation stabilizes.

See what Zim Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes

Current CAPEX is ongoing, primarily focused on two projects similar to previous year's investments.
Newly completed warehouse as part of infrastructure development.
Rs. 181 million added to gross block in Q1, mainly for the new warehouse construction.
No mention of major new CAPEX lined up distinctly for FY24 or FY25 beyond ongoing projects.
Strategic investments include expanding presence in regulated markets like Europe, Australia, and New Zealand through subsidiaries and marketing partners.
Investment in R&D continues strong, with Rs. 53 million spent in Q1 FY24 (~8% of operating income) to support new product innovations and dossier filings.
Focus on diversifying market reach to LATAM, Pharmerging, and other developed markets to improve product quality and returns.
Utilization of funds from escrow shares primarily for reducing cash credit and working capital loans, improving financial health.

Track Zim Laboratories — get its next earnings analysis in your feed

How does Zim Laboratories rank vs peers in ?

Pro feature

ThisZim Laboratories

Rev 3Mar 3

See where Zim Laboratories sits in See which companies these are, and every other name in the sector.Open rankings

What Zim Laboratories's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Zim Laboratories Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Zim Laboratories's management said in earlier quarters